These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26500706)

  • 21. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
    Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
    Nishida Y; Takahashi Y; Tezuka K; Akimoto H; Nakayama T; Asai S
    BMC Pharmacol Toxicol; 2020 Apr; 21(1):28. PubMed ID: 32317005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.
    Odawara M; Yoshiki M; Sano M; Hamada I; Lukashevich V; Kothny W
    Diabetes Ther; 2015 Mar; 6(1):17-27. PubMed ID: 25691359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
    Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
    Katsuno T; Shiraiwa T; Iwasaki S; Park H; Watanabe N; Kaneko S; Terasaki J; Hanafusa T; Imagawa A; Shimomura I; Ikegami H; Koyama H; Namba M; Miyagawa JI;
    Adv Ther; 2021 Mar; 38(3):1514-1535. PubMed ID: 33507500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
    Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
    World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
    Gross JL; Rogers J; Polhamus D; Gillespie W; Friedrich C; Gong Y; Monz BU; Patel S; Staab A; Retlich S
    BMJ Open; 2013 Mar; 3(3):. PubMed ID: 23468467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.